Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 957-963

  Lee, Hyunseung ^a   Lee, Ju Hee ^a   Jung, Kyung Hee ^a   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

Author keywords

Angiogenesis; Apoptosis; Deguelin; Gastric cancer

Indexed keywords

CASPASE 3; CASPASE 9; DEGUELIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN KINASE B; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CHROMATIN CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROTENONE; STOMACH NEOPLASMS;

EID: 77957336029     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000942     Document Type: Article

References (37)

1. Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol 12: 354-362, 2006.
2. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA and Hamilton SM: Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 241: 27-39, 2005.
3. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
4. Clarke JS, Cruze K, El Farra S and Longmire WP Jr: The natural history and results of surgical therapy for carcinoma of the stomach. An analysis of 250 cases. Am J Surg 102: 143-152, 1961.
5. Janunger KG, Hafstrom L, Nygren P and Glimelius B: A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 40: 309-326, 2001. (Pubitemid 32588125)
6. West KA, Linnoila IR, Belinsky SA, Harris CC and Dennis PA: Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res 64: 446-451, 2004.
7. Geeraerts B, Vanhoecke B, Vanden Berghe W, Philippe J, Offner F and Deforce D: Deguelin inhibits expression of Ikappa- Balpha protein and induces apoptosis of B-CLL cells in vitro. Leukemia 21: 1610-1618, 2007.
8. Murillo G, Salti GI, Kosmeder JW II, Pezzuto JM and Mehta RG: Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. Eur J Cancer 38: 2446-2454, 2002.
9. Chun KH, Kosmeder JW III, Sun S, et al: Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 95: 291-302, 2003.
10. Bortul R, Tazzari PL, Billi AM, et al: Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol 129: 677-686, 2005.
11. Lee HY, Suh YA, Kosmeder JW, Pezzuto JM, Hong WK and Kurie JM: Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells. Clin Cancer Res 10: 1074-1079, 2004.
12. Lee HY: Molecular mechanisms of deguelin-induced apoptosis in transformed human bronchial epithelial cells. Biochem Pharmacol 68: 1119-1124, 2004.
13. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
14. Lee HY, Oh SH, Woo JK, et al: Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 97: 1695-1699, 2005.
15. Gerhauser C, Lee SK, Kosmeder JW, et al: Regulation of ornithine decarboxylase induction by deguelin, a natural product cancer chemopreventive agent. Cancer Res 57: 3429-3435, 1997.
16. Hail N Jr and Lotan R: Apoptosis induction by the natural product cancer chemopreventive agent deguelin is mediated through the inhibition of mitochondrial bioenergetics. Apoptosis 9: 437-447, 2004.
17. Udeani GO, Gerhauser C, Thomas CF, et al: Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res 57: 3424-3428, 1997.
18. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
19. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006.
20. Staal SP: Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 84: 5034-5037, 1987.
21. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554, 2004. (Pubitemid 38541907)
22. Sato K, Tamura G, Tsuchiya T, et al: Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer. Virchows Arch 440: 160-165, 2002. (Pubitemid 34169853)
23. Oki E, Baba H, Tokunaga E, et al: Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 117: 376-380, 2005.
24. Yu HG, Ai YW, Yu LL, et al: Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 122: 433-443, 2008.
25. Aligue R, Akhavan-Niak H and Russell P: A role for Hsp90 in cell cycle control: wee1 tyrosine kinase activity requires interaction with Hsp90. EMBO J 13: 6099-6106, 1994.
26. Burrows F, Zhang H and Kamal A: Hsp90 activation and cell cycle regulation. Cell Cycle 3: 1530-1536, 2004.
27. Oh SH, Woo JK, Yazici YD, et al: Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 99: 949-961, 2007.
28. Lee JH, Lee DH, Lee HS, Choi JS, Kim KW and Hong SS: Deguelin inhibits human hepatocellular carcinoma by antiangiogenesis and apoptosis. Oncol Rep 20: 129-134, 2008.
29. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803, 2002.
30. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005.
31. Kim WY, Chang DJ, Hennessy B, et al: A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res 1: 577-587, 2008.
32. Kim WY, Oh SH, Woo JK, Hong WK and Lee HY: Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxiainducible factor-1alpha. Cancer Res 69: 1624-1632, 2009.
33. Oh SH, Woo JK, Jin Q, et al: Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxiainducible factor-1 alpha. Int J Cancer 122: 5-14, 2008.
34. Woo JK, Choi DS, Tran HT, Gilbert BE, Hong WK and Lee HY: Liposomal encapsulation of deguelin: evidence for enhanced antitumor activity in tobacco carcinogen-induced and oncogenic K-ras-induced lung tumorigenesis. Cancer Prev Res 2: 361-369, 2009.
35. Zhang Q, Tang X, Zhang ZF, Velikina R, Shi S and Le AD: Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways. Clin Cancer Res 13: 4686-4694, 2007.
36. Bernardi R, Guernah I, Jin D, et al: PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442: 779-785, 2006.
37. Pore N, Jiang Z, Shu HK, Bernhard E, Kao GD and Maity A: Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 4: 471-479, 2006.